Want to see ALKS full AI Analyst Report?
ALKS Stock Chart & Stats
$34.53
-$0.20(-0.70%)
At close: 4:00 PM EST
$34.53
-$0.20(-0.70%)
Day’s Range― - ―
52-Week Range$25.17 - $55.67
Previous CloseN/A
Volume176.14K
Average Volume (3M)2.31M
Market Cap
$8.62B
Enterprise Value$6.95K
Total Cash (Recent Filing)$511.86M
Total Debt (Recent Filing)$1.58B
Price to Earnings (P/E)55.6
Beta0.67
Next Earnings
Jul 28, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding166,675,810
10 Day Avg. Volume1,696,594
30 Day Avg. Volume2,311,505
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)2.53
Price to Sales (P/S)3.12
P/FCF Ratio9.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$53.92Price Target Upside56.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.38
Revenue Forecast (FY)$1.81B
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Positive Cash GenerationSustained very high gross margins (~84–87% historically) and positive TTM operating cash flow and FCF provide structural capacity to fund R&D, integrate acquisitions, and service debt. This margin base supports durable profitability even if growth moderates, underpinning long‑term reinvestment and resilience.
Diversified Proprietary Portfolio And LUMRYZ Launch MomentumA multi‑brand commercial mix (VIVITROL, ARISTADA, LYBALVI, plus LUMRYZ) reduces revenue concentration risk and supports sustainable top‑line growth. Early LUMRYZ uptake and meaningful sales guidance provide recurring product revenue and predictable cash flow contribution as the brand scales over the next several quarters.
Pipeline Progress And Regulatory IncentivesPositive pivotal data and orphan designations create durable optionality: potential label expansion, regulatory exclusivity, and higher pricing leverage in niche sleep disorders. Ongoing orexin program progression (Phase III/II readouts) supports long‑term product pipeline diversification and clinical differentiation.
Bears Say
Sharp Step‑up In Leverage After Acquisition FinancingA materially higher debt load from the Avadel acquisition and $1.525B term loans reduces financial flexibility and increases interest and refinancing risk. Elevated leverage makes the company more sensitive to growth misses or margin compression and constrains capital allocation over the medium term.
Weakened Cash Flow Momentum And ConversionA sharp decline in free cash flow growth and lower cash conversion suggests working‑capital, inventory step‑up, or timing pressures. With elevated debt, weaker cash momentum impairs the company’s ability to delever, sustain buybacks, or accelerate R&D without restoring consistent cash generation.
Rising Operating Costs And Margin PressureHigher R&D investment and a stepped‑up SG&A run‑rate from integration increase operating leverage, while widening gross‑to‑net negatively impacts product‑level margins. Persistent cost elevation plus pricing/access pressure will compress incremental margins and test sustained profitability absent stronger top‑line expansion.
Alkermes News
ALKS FAQ
What was Alkermes plc’s price range in the past 12 months?
Alkermes plc lowest stock price was $25.16 and its highest was $55.67 in the past 12 months.
What is Alkermes plc’s market cap?
Alkermes plc’s market cap is $8.62B.
When is Alkermes plc’s upcoming earnings report date?
Alkermes plc’s upcoming earnings report date is Jul 28, 2026 which is in 6 days.
How were Alkermes plc’s earnings last quarter?
Alkermes plc released its earnings results on May 05, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.546 by $0.146.
Is Alkermes plc overvalued?
According to Wall Street analysts Alkermes plc’s price is currently Undervalued.
Does Alkermes plc pay dividends?
Alkermes plc does not currently pay dividends.
What is Alkermes plc’s EPS estimate?
Alkermes plc’s EPS estimate is -0.02.
How many shares outstanding does Alkermes plc have?
Alkermes plc has 166,675,810 shares outstanding.
What happened to Alkermes plc’s price movement after its last earnings report?
Alkermes plc reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.546. Following the earnings report the stock price went up 6.087%.
Which hedge fund is a major shareholder of Alkermes plc?
Currently, no hedge funds are holding shares in ALKS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$53.92 (56.14% Upside)
$53.92 (56.14% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 240.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $687.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
104.52%
Trailing 12-Months
Company Description
Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$53.92
▲(56.14% Upside)
Technical Analysis
Ownership Overview
1.43% Insiders
26.14% Mutual Funds
0.47% Other Institutional Investors
40.80% Public Companies and
Individual Investors